Case Report: Rapid resolution of fever after initiation of third-line rescue treatment with upadacitinib for acute severe ulcerative colitis in two young men.

Dan Pinzaru, Martin Kreysing, Tony Lesmeister, Miriam Schwandner, Patrick Michl, Annika Gauss
{"title":"Case Report: Rapid resolution of fever after initiation of third-line rescue treatment with upadacitinib for acute severe ulcerative colitis in two young men.","authors":"Dan Pinzaru, Martin Kreysing, Tony Lesmeister, Miriam Schwandner, Patrick Michl, Annika Gauss","doi":"10.3389/fgstr.2025.1626455","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Acute severe ulcerative colitis (ASUC) is a life-threatening condition in patients with ulcerative colitis with overwhelming systemic inflammation. In case of steroid-refractory courses, the mainstay of therapy is currently infliximab or a calcineurin inhibitor, weighed against colectomy. Recently, Janus kinase (JAK) inhibitors have been shown to result in rapid and persistent responses even in steroid-refractory patients, so that their position in the therapeutic algorithm of ASUC has to be determined. We present-to our best knowledge, for the first time-two cases in which upadacitinib was administered as a third-line rescue therapy in steroid- and infliximab-refractory patients with persistent fever.</p><p><strong>Case presentations: </strong>A 33- and a 28-year-old man, both newly diagnosed with ulcerative pancolitis, presented with steroid-refractory courses of ASUC. Both suffered from fever with temperatures of >39°C in spite of empirical antibiotic therapy, and infection was carefully excluded. In both, infliximab at 5 mg/kg body weight failed to resolve the fever, and second salvage therapy with upadacitinib 45 mg led to swift resolution of the fever and to overall clinical response. Both patients were under ongoing upadacitinib treatment, and in outpatient surveillance, one of them in steroid-free clinical remission up to his last follow-up one year post treatment initiation, the other one up to his last follow-up four months post treatment initiation.</p><p><strong>Conclusion: </strong>Upadacitinib seems to be a valuable option even as a second salvage therapy in ASUC. Randomized controlled trials are warranted. However, it has to be kept in mind that ASUC, especially with septic symptoms such as fever, remains a life-threatening condition in which surgery always has to be evaluated, and that multiple overlapping immunosuppressive therapies may cause severe complications, such as infections.</p>","PeriodicalId":73085,"journal":{"name":"Frontiers in gastroenterology (Lausanne, Switzerland)","volume":"4 ","pages":"1626455"},"PeriodicalIF":0.0000,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12952382/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in gastroenterology (Lausanne, Switzerland)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/fgstr.2025.1626455","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Acute severe ulcerative colitis (ASUC) is a life-threatening condition in patients with ulcerative colitis with overwhelming systemic inflammation. In case of steroid-refractory courses, the mainstay of therapy is currently infliximab or a calcineurin inhibitor, weighed against colectomy. Recently, Janus kinase (JAK) inhibitors have been shown to result in rapid and persistent responses even in steroid-refractory patients, so that their position in the therapeutic algorithm of ASUC has to be determined. We present-to our best knowledge, for the first time-two cases in which upadacitinib was administered as a third-line rescue therapy in steroid- and infliximab-refractory patients with persistent fever.

Case presentations: A 33- and a 28-year-old man, both newly diagnosed with ulcerative pancolitis, presented with steroid-refractory courses of ASUC. Both suffered from fever with temperatures of >39°C in spite of empirical antibiotic therapy, and infection was carefully excluded. In both, infliximab at 5 mg/kg body weight failed to resolve the fever, and second salvage therapy with upadacitinib 45 mg led to swift resolution of the fever and to overall clinical response. Both patients were under ongoing upadacitinib treatment, and in outpatient surveillance, one of them in steroid-free clinical remission up to his last follow-up one year post treatment initiation, the other one up to his last follow-up four months post treatment initiation.

Conclusion: Upadacitinib seems to be a valuable option even as a second salvage therapy in ASUC. Randomized controlled trials are warranted. However, it has to be kept in mind that ASUC, especially with septic symptoms such as fever, remains a life-threatening condition in which surgery always has to be evaluated, and that multiple overlapping immunosuppressive therapies may cause severe complications, such as infections.

Abstract Image

Abstract Image

Abstract Image

病例报告:两名年轻男性急性严重溃疡性结肠炎患者接受upadacitinib三线抢救治疗后发烧迅速消退。
简介:急性严重溃疡性结肠炎(ASUC)是一种危及生命的疾病,溃疡性结肠炎患者伴有压倒性的全身炎症。在类固醇难治性病程的情况下,目前的主要治疗是英夫利昔单抗或钙调磷酸酶抑制剂,权衡结肠切除术。最近,Janus激酶(JAK)抑制剂已被证明即使在类固醇难治性患者中也能产生快速和持续的反应,因此它们在ASUC治疗算法中的位置必须确定。据我们所知,我们首次报道了两例upadacitinib作为持续发热的类固醇和英夫利昔单抗难治性患者的三线抢救治疗。病例介绍:一名33岁和一名28岁的男性,都是新诊断为溃疡性结肠炎,出现了ASUC的类固醇难治性病程。尽管经验性抗生素治疗,但两例患者均出现发热,温度均为50 ~ 39°C,并仔细排除感染。在这两种情况下,5 mg/kg体重的英夫利昔单抗未能退烧,第二次补剂治疗用45 mg的upadacitinib导致发烧迅速消退和总体临床反应。两名患者都在接受持续的upadacitinib治疗,在门诊监测中,其中一名患者在治疗开始一年后的最后一次随访中无类固醇临床缓解,另一名患者在治疗开始后的最后一次随访中四个月。结论:Upadacitinib似乎是一个有价值的选择,甚至作为ASUC的第二抢救治疗。随机对照试验是有必要的。然而,必须记住的是,ASUC,特别是有脓毒性症状(如发烧),仍然是危及生命的疾病,必须评估手术,并且多种重叠的免疫抑制治疗可能导致严重的并发症,如感染。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书